Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVI BioPharma has received a request from Institutional Review Board (IRB) of Nationwide Children's Hospital in Columbus to modify its clinical protocol of eteplirsen Phase 2 clinical trial.
Subscribe to our email newsletter
The company is currently reviewing IRB’s request and expects to submit a revised Phase 2 clinical trial protocol to the board later this month.
AVI BioPharma president and CEO Chris Garabedian said they will work quickly and deliberately to address the IRB’s request and expect to initiate the Phase 2 trial in the third quarter.
"Furthermore, we are confident that we will remain on track in initiating a pivotal trial in the second half of 2012," Garabedian said.
"We remain fully committed to eteplirsen development and its potential as an important treatment for DMD."